The objectives of this study were to determine the effect of cadmium (Cd) on glucose metabolism disruption in liver cells homogenate in vitro. The glucose metabolism disruption was analyzed by measuring the level of liver glucose, glycogen and methylglyoxal (MG), and the activity of glucokinase activity. In this experiment, a liver sample was taken from male rats (Rattus novergicus). Samples then homogenized and divided into four groups with; C served as control which contains liver homogenate only; T1 which contains liver homogenate + 0.03 mg/l of cadmium sulphate (CdSO4); T2 which contains liver homogenate + 0.3 mg/l of CdSO4; and T3 which contains liver homogenate + 3 mg/l of CdSO4. After treatment, liver glucose, glycogen, and MG levels, and glucokinase activity were estimated. The activity of liver glucokinase was estimated by measuring the Michaelis-Menten constant (Km) value. The results revealed that Cd exposure could significantly increase glucose and MG levels, the Km value of glucokinase, and decreased the glycogen level in liver cells (P>0.05). These results indicated that Cd exposure induced the disruption of glucose metabolism in the liver.

Background: There is still very limited study available for patency of arteriovenous fistulas (AVF) from developing country, specifically in East Borneo, Indonesia. The aim of this study is to compare the primary patency rate between radiocephalic (RC) and brachiocephalic (BC) AVF and to analyze the risk factors involved in the primary patency results of AVF RC and BC for hemodialysis. Methods: This study is a retrospective cohort study with a total of 154 patients underwent AVF from February 2017 until august 2018 and were monitored until august 2019. The patient’s primary patency of AVF was evaluated by the Kaplan-Meier survival curve. Each of the risk factors that were predicted to influence patency was analyzed for each AVF. Result: The mean age of 154 patients was 52.9 ± 9.5 years old. RC AVF was made in 130 patients (84.4%) and BC AVF was made in 24 patients (15.6%). There was no significant difference between the estimated primary patency for the RC group and BC AVF, the log-rank test (p=0.15). Risk factors for age, gender, hypertension, DM, and frequency of hemodialysis in both AVF showed statistically insignificant for primary patency. Conclusion: Our study showed there was no significant difference in the primary patency rate between the RC AVF and BC AVF group and other risk factors not significantly affecting primary patency in either type of AVF.